Kyntra Bio, Inc. (KYNB) stock

KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30

$3.44−0.15 (-4.18%)

Close on Nov 13, 2026Market cap $13.93MP/E 0.1Yield –

Kyntra Bio EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Kyntra Bio's EV/EBITDA was 97.9× on Jan 31, 2020.

Period	Period end	Value	Change (pts)
2020	Jan 31, 2020	97.9×	−2.9
2019	Dec 31, 2019	100.9×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is KYNB.

Revenue growth-37.1% · median -0.5%

Operating margin-1089.8% · median -1741.2%

Net margin3967.8% · median -1685.3%

Advertisement
300 × 250

See a number that looks wrong?